Thomas Loesevitz, DO
Family Medicine · Radcliff, KYNPI 1558755108
Payments from drug & device makers
Across 289 payments — averaging $16.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$624
- AbbVie$619
- Amgen$384
- GSK$372
- Pfizer$318
- Lilly USA, LLC$306
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,643100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 45 | $624 |
| AbbVie(2 entities) | 42 | $619 |
| Amgen | 24 | $384 |
| GSK | 25 | $372 |
| Pfizer | 21 | $318 |
| Lilly USA, LLC | 21 | $306 |
| Astellas Pharma US Inc | 12 | $219 |
| Bayer | 10 | $160 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $154 |
| Sumitomo Pharma America, Inc. | 6 | $114 |
| Sanofi-aventis U.S. LLC | 7 | $100 |
| Idorsia Pharmaceuticals US Inc | 6 | $98 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $86 |
| Exact Sciences | 4 | $81 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $78 |
| Aclaris Therapeutics, Inc. | 1 | $76 |
| Merck | 4 | $72 |
| AstraZeneca | 5 | $72 |
| Insulet Corporation | 4 | $72 |
| Boehringer Ingelheim | 5 | $72 |
| Novartis | 4 | $65 |
| Axsome Therapeutics, Inc. | 3 | $64 |
| Vanda Pharmaceuticals Inc. | 3 | $63 |
| Xeris Pharmaceuticals, Inc. | 3 | $62 |
| Medtronic | 2 | $55 |
| Johnson & Johnson | 3 | $54 |
| Kowa Pharmaceuticals America, Inc. | 2 | $34 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $31 |
| Tris Pharma Inc | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Dynavax Technologies Corporation | 1 | $15 |
| Dexcom, Inc. | 1 | $15 |
| Abbott | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
| Inogen, Inc. | 1 | $10 |
How this compares
$4,643 in reported general payments places this provider in the 80th percentile of 1,559 family medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 58 | $63,196 |
| EliquisApixaban | 25 | $25,913 |
| OzempicSemaglutide | 20 | $25,786 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $23,228 |
| XareltoRivaroxaban | 15 | $12,562 |
| LinzessLinaclotide | 13 | $12,237 |
| JanuviaSitagliptin Phosphate | 17 | $11,779 |
| FarxigaDapagliflozin Propanediol | 15 | $8,552 |
| Pregabalin | 26 | $1,468 |
| Methylphenidate ErMethylphenidate Hcl | 12 | $1,351 |
| Levothyroxine Sodium | 98 | $983 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 66 | $923 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 57 | $876 |
| Atorvastatin Calcium | 185 | $863 |
| Ezetimibe | 31 | $800 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $72 | $63,19658 claims |
| PfizerEliquis | $318 | $25,91325 claims |
| Novo NordiskOzempic | $624 | $25,78620 claims |
| GSKTrelegy Ellipta | $372 | $23,22828 claims |
| Johnson & JohnsonXarelto | $54 | $12,56215 claims |
| AbbVieLinzess | $619 | $12,23713 claims |
| MerckJanuvia | $72 | $11,77917 claims |
| AstraZenecaFarxiga | $72 | $8,55215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Radcliff
- Brian SmithVersailles$7.7M
- Barbara Fleming-PhillipsLexington$1.4M
- Christopher RhyneLouisville$1M
- Kruti PatelBurlington$463K
- Michael LovelaceLouisville$244K
- John RichardLexington$226K
- Diego MastronardiBowling Green$196K
- James TurnboPaducah$124K
- Eleida Tur OlivaLexington$113K
- Jeffrey GreenParis$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.